Documenting Prior Therapy for Appeal Success

If there is one documentation failure that accounts for more lost appeals than any other, it is the incomplete or absent record of prior therapy. Payers require evidence that a patient has tried and failed appropriate first-line treatments before approving higher-cost alternatives. When that evidence is missing from the medical record — or present but too vague to satisfy payer criteria — the appeal fails regardless of how medically appropriate the requested treatment may be.

This is a solvable problem. It does not require new technology or additional staff. It requires a consistent, disciplined approach to documenting prior therapy at the point of care, every time.

What Payers Actually Need to See

The standard for documenting prior therapy is higher than many practices realize. "Patient tried methotrexate without improvement" is insufficient for virtually every payer. What payers require is a complete narrative for each prior therapy that answers five questions:

1. What was the therapy? Medication name (generic preferred, with brand if relevant), formulation, and route of administration.
2. What was the dose? The specific dose prescribed, including any dose escalations during the trial period.
3. How long was it tried? Start date and end date (or duration), establishing whether the trial meets the payer's definition of "adequate."
4. What was the response? Objective outcome measures — disease activity scores, lab values, functional assessments — documented before and after the therapy trial.
5. Why was it discontinued? The specific clinical reason: inadequate efficacy, adverse reaction (with description), contraindication identified during treatment, or disease progression despite therapy.

Each of these five elements serves a specific purpose in the payer's review. The therapy name and dose confirm that the correct medication was used at a therapeutic level. The duration confirms that it was given a fair trial. The response data confirms that it failed objectively, not just subjectively. The discontinuation reason explains why continuing or re-trying the therapy is not appropriate.

The "Adequate Trial" Standard

Payers define minimum trial durations for most step therapy protocols, and these definitions vary by payer and by medication class. Common examples:

• Conventional DMARDs for RA: Typically 12 to 16 weeks at therapeutic doses (e.g., methotrexate 15-25mg weekly) per ACR recommendations
• Oral bisphosphonates for osteoporosis: Often 12 months, with a follow-up DXA or evidence of fracture during therapy
• Oral preventive medications for migraine: Usually 6 to 8 weeks at adequate dose per each medication class
• Topical therapies for dermatologic conditions: Varies widely, typically 4 to 12 weeks depending on the condition
• Oral diabetes medications: Generally 3 months, with HbA1c measurement demonstrating inadequate glycemic control

If the patient's documented trial falls short of the payer's minimum — three weeks of methotrexate instead of twelve, or 10mg instead of 15mg — the payer will deny the appeal on the grounds that the first-step therapy was not adequately tried. The documentation must demonstrate that the trial met the specific parameters the payer requires.

Documenting Adverse Reactions

When a therapy was discontinued due to an adverse reaction rather than inefficacy, the documentation standards are different but equally specific. The record should include:

• The specific adverse reaction experienced (not just "side effects")
• The severity and clinical significance of the reaction
• When the reaction occurred relative to starting the medication
• Whether the dose was reduced or supportive measures were attempted
• Whether the reaction resolved after discontinuation

A note documenting "Patient developed significant GI symptoms and discontinued methotrexate" is vague. A note documenting "Patient developed persistent nausea and vomiting within 48 hours of each weekly dose despite antiemetic premedication, dose reduction to 15mg, and switch from oral to subcutaneous administration. Symptoms prevented adequate nutritional intake and resulted in 8-pound weight loss over 6 weeks. Methotrexate discontinued on [date] with resolution of symptoms within 2 weeks" is specific, credible, and difficult for a payer to challenge.

The Challenge of Historical Documentation

Not all prior therapy occurs within the current practice or the current EHR. Patients transfer between providers, switch insurance plans, and have treatment histories that span multiple healthcare systems. When the evidence of a prior therapy trial exists only in a previous provider's records, the current practice faces a documentation gap that can derail an appeal.

Several approaches can address this challenge:

• Request records from prior providers. This is the gold standard — obtaining the actual clinical documentation from the prescribing physician. It takes time but provides the most authoritative evidence.
• Pharmacy records. Prescription fill history from the patient's pharmacy or pharmacy benefit manager can document that a medication was dispensed, the dose, and the fill dates — establishing at minimum that the therapy was prescribed and filled.
• Patient medication history tools. Many EHR systems include medication history features that pull from pharmacy databases, providing a timeline of prescriptions that can corroborate the patient's reported treatment history.
• Physician attestation with patient corroboration. When records are unavailable, a detailed note in which the physician documents the patient's reported treatment history — including specific medications, approximate dates, and reasons for discontinuation — with a notation that external records were requested but unavailable, can serve as supporting evidence. This is the weakest form of documentation and should be supplemented with any available corroborating records.

Building Prior Therapy Documentation Into Workflow

The practices that handle prior therapy documentation most effectively do not rely on retrospective chart review. They build the documentation into their clinical workflow at predictable trigger points.

At New Patient Intake

When a new patient establishes care, the intake process should include a structured medication history that captures not just current medications but prior medications for the conditions the practice will manage. For each prior medication, the intake form should collect the medication name, approximate dose, approximate duration, reason for discontinuation, and whether it was effective or not.

At Treatment Decision Points

When a physician decides to prescribe a medication that is likely to require prior authorization, the encounter note should include a summary of the prior therapy history that supports the prescribing decision. This "prior therapy summary" — written at the time the treatment decision is made — becomes part of the medical record and is immediately available for the prior authorization submission.

At Each Follow-Up During Active Therapy

For patients currently on a therapy that may need to be escalated, each follow-up visit should document the current therapy (name, dose, duration to date), objective response measures, and the clinical assessment of whether the therapy is providing adequate benefit. This creates a contemporaneous, longitudinal record that is far more credible than a retrospective summary.

The Revenue Impact

The financial consequence of poor prior therapy documentation is direct and measurable. Every appeal that fails because the record cannot demonstrate an adequate trial of the required step therapy represents lost revenue — the cost of the denied treatment, the cost of the appeal staff time, and the opportunity cost of delayed patient care. For specialty practices where step therapy denials are common, improving prior therapy documentation can shift appeal outcomes materially.

The information exists. Patients know what they have tried. Physicians know what they have prescribed. The challenge is capturing that knowledge in the medical record with the specificity and consistency that payers require. Practices that solve this challenge find that many of their step therapy denials simply stop occurring.